John Oyler Sells 54,892 Shares of BeOne Medicines (NASDAQ:ONC) Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) CEO John Oyler sold 54,892 shares of BeOne Medicines stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $358.15, for a total value of $19,659,569.80. Following the completion of the transaction, the chief executive officer directly owned 240,743 shares of the company’s stock, valued at approximately $86,222,105.45. This represents a 18.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

John Oyler also recently made the following trade(s):

• On Tuesday, August 11th, John Oyler sold 70,907 shares of BeOne Medicines stock. The stock was sold at an average price of $361.90, for a total transaction of $25,661,243.30.
• On Monday, August 10th, John Oyler sold 115,011 shares of BeOne Medicines stock. The shares were sold at an average price of $357.87, for a total transaction of $41,158,986.57.
• On Monday, July 20th, John Oyler sold 48,316 shares of BeOne Medicines stock. The shares were sold at an average price of $312.25, for a total transaction of $15,086,671.00.
• On Tuesday, July 21st, John Oyler sold 61,397 shares of BeOne Medicines stock. The shares were sold at an average price of $317.67, for a total transaction of $19,503,984.99.
• On Friday, July 10th, John Oyler sold 11,698 shares of BeOne Medicines stock. The stock was sold at an average price of $298.34, for a total transaction of $3,489,981.32.
• On Monday, July 13th, John Oyler sold 48,520 shares of BeOne Medicines stock. The stock was sold at an average price of $304.35, for a total transaction of $14,767,062.00.
• On Tuesday, July 14th, John Oyler sold 145,861 shares of BeOne Medicines stock. The shares were sold at an average price of $305.95, for a total transaction of $44,626,172.95.
• On Tuesday, June 23rd, John Oyler sold 3,410 shares of BeOne Medicines stock. The shares were sold at an average price of $273.78, for a total transaction of $933,589.80.
• On Tuesday, June 16th, John Oyler sold 3,693 shares of BeOne Medicines stock. The stock was sold at an average price of $265.55, for a total transaction of $980,676.15.
• On Thursday, June 11th, John Oyler sold 1,949 shares of BeOne Medicines stock. The stock was sold at an average price of $257.24, for a total value of $501,360.76.

BeOne Medicines Stock Down 0.1%

Shares of BeOne Medicines stock traded down $0.22 during trading hours on Wednesday, reaching $359.05. 314,911 shares of the company were exchanged, compared to its average volume of 289,218. The firm has a market cap of $39.39 billion, a PE ratio of 63.21 and a beta of 0.49. The company has a debt-to-equity ratio of 0.17, a quick ratio of 3.06 and a current ratio of 3.40. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $385.22. The stock’s fifty day moving average is $299.80 and its 200 day moving average is $308.98.

BeOne Medicines (NASDAQ:ONC) last released its earnings results on Wednesday, August 5th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $1.40 by $0.65. BeOne Medicines had a return on equity of 14.23% and a net margin of 10.70%.The firm had revenue of $1.71 billion during the quarter, compared to analysts’ expectations of $1.66 billion. As a group, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 7.3 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Wall Street Zen raised BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research report on Saturday, July 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Friday, July 17th. Truist Financial boosted their price target on shares of BeOne Medicines from $416.00 to $418.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Barclays increased their price objective on shares of BeOne Medicines from $403.00 to $407.00 and gave the company an “overweight” rating in a research report on Thursday, August 6th. Finally, Guggenheim lifted their price objective on shares of BeOne Medicines from $420.00 to $430.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $402.14.

Institutional Investors Weigh In On BeOne Medicines

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Mariner LLC boosted its position in shares of BeOne Medicines by 3.8% in the 4th quarter. Mariner LLC now owns 883 shares of the company’s stock valued at $269,000 after purchasing an additional 32 shares during the period. Farther Finance Advisors LLC lifted its stake in BeOne Medicines by 21.8% in the fourth quarter. Farther Finance Advisors LLC now owns 218 shares of the company’s stock valued at $66,000 after buying an additional 39 shares during the last quarter. CWM LLC boosted its holdings in shares of BeOne Medicines by 32.8% in the fourth quarter. CWM LLC now owns 158 shares of the company’s stock valued at $48,000 after acquiring an additional 39 shares during the period. Steadtrust LLC boosted its holdings in shares of BeOne Medicines by 3.7% in the second quarter. Steadtrust LLC now owns 1,400 shares of the company’s stock valued at $399,000 after acquiring an additional 50 shares during the period. Finally, Benjamin Edwards Inc. grew its position in shares of BeOne Medicines by 8.0% during the fourth quarter. Benjamin Edwards Inc. now owns 690 shares of the company’s stock worth $210,000 after acquiring an additional 51 shares during the last quarter. Institutional investors and hedge funds own 48.55% of the company’s stock.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.